Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

En undersøgelse af kombinationsbehandling med amivantamab og carboplatin-pemetrexed, sammenlignet med carboplatin-pemetrexed, hos deltagere med avanceret eller metastatisk ikke-småcellet lungekræft karakteriseret ved epidermal vækstfaktorreceptor (EGFR) Exon 20 insertioner (PAPILLON)

2. november 2026 opdateret af: Janssen Research & Development, LLC

61186372NSC3001: A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

308

Fase

  • Fase 3

Udvidet adgang

Godkendt til salg til offentligheden. Se udvidet adgangsregistrering.

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Camperdown, Australien, 2050
        • Chris O'Brien Lifehouse
      • Kogarah, Australien, 2217
        • St George Hospital
      • Malvern, Australien, 3144
        • Cabrini Medical Centre
      • Nedlands, Australien, 6009
        • Sir Charles Gairdner Hospital
      • Leuven, Belgien, 3000
        • UZ Leuven
      • Roeselare, Belgien, 8800
        • Algemeen Ziekenhuis Delta
      • Yvoir, Belgien, 5530
        • CHU UCL Namur - Site Godinne
      • Barretos, Brasilien, 14784-400
        • Fundacao Pio XII
      • Belo Horizonte, Brasilien, 30110-017
        • Cetus Oncologia
      • Florianópolis, Brasilien, 88020-210
        • Ynova Pesquisa Clinica
      • Ijuí, Brasilien, 98700-000
        • Oncosite - Centro de Pesquisa Clínica em Oncologia Ltda
      • Natal, Brasilien, 59062 000
        • Liga Norte Riograndense Contra O Cancer
      • Pelotas, Brasilien, 96020 080
        • UPCO Unidade de Pesquisa Clinica em Oncologia
      • Porto Alegre, Brasilien, 90020-090
        • Irmandade Santa Casa de Misericordia de Porto Alegre
      • Porto Alegre, Brasilien, 90610-000
        • Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
      • Rio de Janeiro, Brasilien, 22 250 905
        • Oncoclinicas Rio de Janeiro S A
      • Rio de Janeiro, Brasilien, 22281 100
        • Instituto D Or de Pesquisa e Ensino IDOR
      • Rio de Janeiro, Brasilien, 20231 050
        • Ministerio da Saude Instituto Nacional do Cancer
      • Sorocaba, Brasilien, 18030-075
        • IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado
      • São Paulo, Brasilien, 04014-002
        • Núcleo de Pesquisa São Camilo
      • São Paulo, Brasilien, 01509 900
        • Fundacao Antonio Prudente A C Camargo Cancer Center
      • São Paulo, Brasilien, 01246 000
        • Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
      • Vitória, Brasilien, 29308-014
        • Hospital Evangélico de Cachoeiro de Itapemirim
    • Ontario
      • Ottawa, Ontario, Canada, K1H 8L6
        • The Ottawa Hospital Cancer Centre
      • Toronto, Ontario, Canada, M4N 3M5
        • Sunnybrook Health Sciences Centre
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • McGill University Health Centre
      • Edinburgh, Det Forenede Kongerige, EH4 2XU
        • Edinburgh Cancer Centre Western General
      • London, Det Forenede Kongerige, SW3 6JJ
        • The Royal Marsden NHS Trust Chelsea
      • Sutton, Det Forenede Kongerige, SM2 5PT
        • The Royal Marsden NHS Trust Sutton
    • California
      • Duarte, California, Forenede Stater, 91010
        • City of Hope 2
      • Orange, California, Forenede Stater, 92868
        • University of California Irvine
      • Santa Monica, California, Forenede Stater, 90404
        • UCLA
    • District of Columbia
      • Washington D.C., District of Columbia, Forenede Stater, 20007
        • Georgetown University Hospital
    • Florida
      • Tampa, Florida, Forenede Stater, 33612
        • H. Lee Moffitt Cancer & Research Institute
    • Georgia
      • Athens, Georgia, Forenede Stater, 30607
        • University Cancer And Blood Center LLC
    • Michigan
      • Detroit, Michigan, Forenede Stater, 48202
        • Henry Ford Hospital
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63110
        • Washington University Medical Center
    • New Jersey
      • East Brunswick, New Jersey, Forenede Stater, 08816
        • Regional Cancer Care Associates LLC
    • New York
      • New York, New York, Forenede Stater, 10032
        • Columbia University Medical Center
      • New York, New York, Forenede Stater, 10016
        • Langone Health at NYC University, NYU School of Medicine
    • Oregon
      • Portland, Oregon, Forenede Stater, 97213
        • Providence Portland Medical Center
    • South Dakota
      • Sioux Falls, South Dakota, Forenede Stater, 57104
        • Sanford Health
    • Texas
      • Tyler, Texas, Forenede Stater, 75702
        • Texas Oncology Pa
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84106
        • Utah Cancer Specialists
    • Virginia
      • Fairfax, Virginia, Forenede Stater, 22031
        • Virginia Cancer Specialists
      • Salem, Virginia, Forenede Stater, 24153
        • Blue Ridge Cancer Care
      • Bordeaux, Frankrig, 33000
        • Institut Bergonie
      • Bron, Frankrig, 69500
        • Hospices Civils de Lyon HCL
      • Dijon, Frankrig, 21000
        • Centre Georges Francois Leclerc
      • Le Mans, Frankrig, 72037
        • Centre Hospitalier Le Mans
      • Lille, Frankrig, 59037
        • CHR Hôpital Calmette
      • Nantes, Frankrig, 44093
        • CHU Nantes - Hopital Nord Laënnec
      • Paris, Frankrig, 75005
        • Institut Curie
      • Pessac, Frankrig, 33604
        • CHU Bordeaux
      • Saint-Mandé, Frankrig, 94163
        • HIA Begin
      • Hyderabad, Indien, 500034
        • Basavatarakam Indo-American Hospital
      • Kolkata, Indien, 700160
        • Tata Medical Center
      • Mumbai, Indien, 400012
        • Tata Memorial Hospital
      • Nashik, Indien, 422002
        • HCG Manavta Cancer Centre
      • New Delhi, Indien, 110085
        • Rajiv Gandhi Cancer Institute & Research Centre
      • Pune, Indien, 411013
        • Noble Hospital Pvt Ltd
      • Jerusalem, Israel, 91031
        • Shaare Zedek Medical Center
      • Jerusalem, Israel, 9112001
        • Hadassah Medical Center
      • Kfar Saba, Israel, 44281
        • Meir Medical Center
      • Petah Tikva, Israel, 49100
        • Rabin Medical Center
      • Tel Aviv, Israel, 6423906
        • Tel Aviv Sourasky Medical Center
      • Bologna, Italien, 40138
        • A O U Sant Orsola Malpighi
      • Catania, Italien, 95123
        • Azienda Ospedaliero Univ. Policlinico Gaspare Rodolico
      • Meldola, Italien, 47014
        • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
      • Milan, Italien, 20132
        • IRCCS Ospedale San Raffaele
      • Milan, Italien, 20133
        • Fondazione IRCCS Istituto Nazionale dei Tumori
      • Milan, Italien, 20122
        • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
      • Monza, Italien, 20052
        • San Gerardo Hospital
      • Ravenna, Italien, 48121
        • Ospedale S. Maria Delle Croci
      • Roma, Italien, 00168
        • Irccs Gemelli
      • Rozzano, Italien, 20089
        • Istituto Clinico Humanitas
      • Bunkyō City, Japan, 113 8431
        • Juntendo University Hospital
      • Hidaka, Japan, 350-1298
        • Saitama Medical University International Medical Center
      • Himeji, Japan, 670-8520
        • National Hospital Organization Himeji Medical Center
      • Hirakata, Japan, 573 1191
        • Kansai Medical University Hospital
      • Kanazawa, Japan, 920 8641
        • Kanazawa University Hospital
      • Kashiwa, Japan, 277 8577
        • National Cancer Center Hospital East
      • Kishiwada, Japan, 596-8501
        • Kishiwada City Hospital
      • Kobe, Japan, 650-0047
        • Kobe City Medical Center General Hospital
      • Kurashiki, Japan, 710-8602
        • Kurashiki Central Hospital
      • Kurume, Japan, 830-0011
        • Kurume University Hospital
      • Matsusaka, Japan, 515-8544
        • Matsusaka Municipal Hospital
      • Nagoya, Japan, 460-0001
        • National Hospital Organization Nagoya Medical Center
      • Nagoya, Japan, 464 8681
        • Aichi Cancer Center Hospital
      • Niigata, Japan, 951-8566
        • Niigata Cancer Center Hospital
      • Osaka Sayama Shi, Japan, 589 8511
        • Kindai University Hospital
      • Sagamihara, Japan, 252-0375
        • Kitasato University Hospital
      • Sapporo, Japan, 060-8648
        • Hokkaido University Hospital
      • Shiwa-gun, Japan, 028-3695
        • Iwate Medical University Hospital
      • Shizuoka, Japan, 411 8777
        • Shizuoka Cancer Center
      • Tokyo, Japan, 135 8550
        • The Cancer Institute Hospital of JFCR
      • Toon-shi, Japan, 791-0295
        • Ehime University Hospital
      • Wakayama, Japan, 641 8510
        • Wakayama Medical University Hospital
      • Yamaguchi, Japan, 755-0241
        • National Hospital Organization Yamaguchi Ube Medical Center
      • Beijing, Kina, 100142
        • Beijing Cancer Hospital
      • Beijing, Kina, 100853
        • Chinese PLA General Hospital
      • Beijing, Kina, 102206
        • Peking University International Hospital
      • Beijing, Kina, 100142
        • Beijing Cancer Hospital Chest Tumor Internal Medicine dept. II
      • Beijing, Kina, 101199
        • Beijing Chest hospital, Capital medical university
      • Changchun, Kina, 130000
        • Jilin cancer hospital
      • Changsha, Kina, 410013
        • Hunan Cancer Hospital Chest Tumor Internal Medicine dept. II
      • Changsha, Kina, 410013
        • Hunan Cancer hospital
      • Changzhou, Kina, 213003
        • The First People's Hospital Of Changzhou
      • Chengdu, Kina, 610041
        • West China Hospital Sichuan University
      • Chongqing, Kina, 400030
        • Chongqing University Cancer Hospital
      • Fuzhou, Kina, 350001
        • Fujian Medical University Union Hospital
      • Guangzhou, Kina, 510080
        • The First Affiliated Hospital Sun Yat sen University
      • Hangzhou, Kina, 310022
        • Zhejiang Cancer Hospital
      • Hangzhou, Kina, 310009
        • The Second Affiliated Hospital of Zhejiang University College of Medicine
      • Hangzhou, Kina, 310003
        • The First Affiliated Hospital Zhejiang University College of Medicine
      • Hangzhou, Kina, 310016
        • Sir Run Run Shaw Hospital Zhejiang University School of Medicine
      • Hangzhou, Kina, 310009
        • The Second Affiliated Hospital of Zhejiang University College of Medicine 1
      • Harbin, Kina, 150000
        • Harbin medical university cancer hospital
      • Linhai, Kina, 317000
        • Taizhou Hospital of Zhejiang Province
      • Nanjing, Kina, 210031
        • Nanjing Drum Tower Hospital
      • Shanghai, Kina, 200030
        • Shanghai Chest Hospital
      • Shanghai, Kina, 200032
        • Fudan University Shanghai Cancer Center
      • Shanghai, Kina, 200433
        • Shanghai Pulmonary Hospital
      • Shanghai, Kina, 200123
        • Shanghai East Hospital
      • Shenyang, Kina, 110004
        • Shengjing Hospital Of China Medical University
      • Shenzhen, Kina, 518116
        • Cancer hospital Chinese Academy of Medical Sciences, Shenzhen Center
      • Tianjin, Kina, 300052
        • Tianjin Medical University General Hospital
      • Weifang, Kina, 261000
        • Weifang People's Hospital
      • Wuhan, Kina, 430030
        • TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology
      • Wuxi, Kina, 214122
        • Hospital of Jiangnan University
      • Xi'an, Kina, 710061
        • The First Affiliated Hospital of Xian Jiaotong University
      • Yantai, Kina, 264000
        • Yantai Yuhuangding Hospital
      • Zhengzhou, Kina, 450008
        • Henan Cancer Hospital
      • George Town, Malaysia, 10990
        • Hospital Pulau Pinang
      • Johor Bahru, Malaysia, 81100
        • Hospital Sultan Ismail
      • Kuala Lumpur, Malaysia, 50586
        • Hospital Kuala Lumpur
      • Kuala Lumpur, Malaysia, 59100
        • University Malaya Medical Centre
      • Chihuahua City, Mexico, 31217
        • Centro Oncologico de Chihuahua
      • Guadalajara, Mexico, 44280
        • Hospital Civil de Guadalajara Fray Antonio Alcalde
      • Mexico City, Mexico, 14080
        • Instituto Nacional de Cancerologia
      • Mexico City, Mexico, 14050
        • Médica Sur
      • Mexico City, Mexico, 03100
        • Mexico Centre for Clinical Research, S.A. de C.V.
      • Monterrey, Mexico, 64710
        • i Can Oncology Center
      • México, Mexico, 03100
        • Health Pharma Professional Research
      • Naucalpan, Mexico, 53100
        • Oncologia Integral Satelite
      • Bydgoszcz, Polen, 85 796
        • Centrum Onkologii im Prof F Lukaszczyka
      • Gdansk, Polen, 80 214
        • Uniwersyteckie Centrum Kliniczne
      • Gdynia, Polen, 81 519
        • Szpitale Pomorskie Sp z o o
      • Olsztyn, Polen, 10-357
        • Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie
      • Poznan, Polen, 60-693
        • Private Specialist Hospitals - MedPolonia
      • Warsaw, Polen, 02-781
        • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
      • Lisbon, Portugal, G1R 2J6
        • Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos
      • Lisbon, Portugal, 1998-018
        • Hosp. Cuf Descobertas
      • Porto, Portugal, 4200-072
        • Instituto Portugues de Oncologia
      • Porto, Portugal, 4099-001
        • Centro Hospitalar Universitario do Porto, EPE
      • Vila Nova de Gaia, Portugal, 4434 502
        • Centro Hospitalar de Vila Nova de Gaia Espinho E P E
      • Rio Piedras, Puerto Rico, 00935
        • Pan American Center for Oncology Trials LLC
      • Irkutsk, Rusland, 664035
        • Irkutsk Regional Oncology Dispensary
      • Krasnogorsk, Rusland, 143423
        • Moscow City Oncology Hospital No 62
      • Krasnoyarsk, Rusland, 660133
        • Krasnoyarsk Regional Oncology Dispensary
      • Kuzmolovsky, Rusland, 188663
        • Leningrad Regional Oncology Dispensary
      • Moscow, Rusland, 115533
        • MCK
      • Nal'chik, Rusland, 360000
        • City Clinical Hospital #1
      • Nizhny Novgorod, Rusland, 603000
        • Nizhny Novgorod Regional Oncological Dispensary
      • Saint Petersburg, Rusland, 197758
        • N.N. Petrov Research Institute Of Oncology
      • Saint Petersburg, Rusland, 194291
        • Leningrad Regional Clinical Hospital
      • Saint Petersburg, Rusland, 196006
        • Oncology Medical Clinics AV Medical group
      • Tomsk, Rusland, 634050
        • Tomsk Cancer Research Institute
      • Ufa, Rusland, 450083
        • Bashkir State Medical University
      • Yaroslavl, Rusland, 150054
        • Yaroslavl Regional Clinical Oncology Hospital
      • A Coruña, Spanien, 15006
        • Hosp Univ A Coruna
      • Badalona, Spanien, 08916
        • Inst. Cat. D'Oncologia-Badalona
      • Barcelona, Spanien, 08025
        • Hosp. de La Santa Creu I Sant Pau
      • Barcelona, Spanien, 08028
        • Hosp. Univ. Quiron Dexeus
      • Barcelona, Spanien, 08035
        • Hosp Univ Vall D Hebron
      • Burgos, Spanien, 09003
        • Hosp. Univ. de Burgos
      • Madrid, Spanien, 28041
        • Hosp. Univ. 12 de Octubre
      • Madrid, Spanien, 28034
        • Hosp. Univ. Ramon Y Cajal
      • Madrid, Spanien, 28046
        • Hosp. Univ. La Paz
      • Madrid, Spanien, 28007
        • Hosp. Gral. Univ. Gregorio Maranon
      • Majadahonda, Spanien, 28222
        • Hosp. Univ. Pta. de Hierro Majadahonda
      • Málaga, Spanien, 29010
        • Hosp Virgen de La Victoria
      • Pamplona, Spanien, 31008
        • Clinica Univ. de Navarra
      • Seville, Spanien, 41013
        • Hosp. Virgen Del Rocio
      • Zaragoza, Spanien, 50009
        • Hosp. Clinico Univ. Lozano Blesa
      • Busan, Sydkorea, 48108
        • Inje University Haeundae Paik Hospital
      • Gyeonggi-do, Sydkorea, 10408
        • National Cancer Center 1
      • Gyeongsangnam-do, Sydkorea, 52727
        • GyeongSang National University Hospital
      • Jeollanam-do, Sydkorea, 58128
        • Chonnam National University Hwasun Hospital
      • Seongnam-si, Sydkorea, 13620
        • Seoul National University Bundang Hospital
      • Seoul, Sydkorea, 05505
        • Asan Medical Center
      • Seoul, Sydkorea, 03722
        • Severance Hospital Yonsei University Health System
      • Seoul, Sydkorea, 06351
        • Samsung Medical Center
      • Seoul, Sydkorea, 03181
        • Kangbuk Samsung Hospital
      • Seoul, Sydkorea, 02841
        • Korea University Anam Hospital
      • Seoul, Sydkorea, 06591
        • The Catholic University of Korea Seoul St Mary s Hospital
      • Kaohsiung City, Taiwan, 807
        • Kaohsiung Medical University Chung Ho Memorial Hospital
      • Kaohsiung City, Taiwan, 833
        • Chang Gung Medical Foundation
      • New Taipei City, Taiwan, 23561
        • Taipei Medical University Shuang Ho Hospital
      • Taichung, Taiwan, 40447
        • China Medical University Hospital
      • Taichung, Taiwan, 402
        • Chung Shan Medical University Hospital
      • Taipei, Taiwan, 10002
        • National Taiwan University Hospital
      • Bangkok, Thailand, 10700
        • Siriraj Hospital
      • Bangkok, Thailand, 10400
        • Phramongkutklao Hospital and Medical College
      • Songkhla, Thailand, 90110
        • Songklanagarind Hospital, Prince of Songkla University
      • Adana, Tyrkiet (Türkiye), 01060
        • Adana City Hospital
      • Adana, Tyrkiet (Türkiye), 01250
        • Başkent University Medical Faculty Adana Application and Research Center
      • Ankara, Tyrkiet (Türkiye), 6560
        • Gazi University Hospital
      • Ankara, Tyrkiet (Türkiye), 6800
        • Ankara Bilkent City Hospital
      • Edirne, Tyrkiet (Türkiye), 22030
        • Trakya University Medical Faculty
      • Istanbul, Tyrkiet (Türkiye), 34722
        • Goztepe Prof Dr Suleyman Yalcin Sehir Hastanesi
      • Istanbul, Tyrkiet (Türkiye), 34098
        • Istanbul Universitesi Cerrahpasa Tip Fakultesi Ic Hastaliklari Anabilim Dali Medikal Onkoloji Bd
      • Istanbul, Tyrkiet (Türkiye), 34214
        • Medipol Mega University Hospital
      • Izmir, Tyrkiet (Türkiye), 35580
        • Izmir Medical Park Hospital
      • Bad Berka, Tyskland, 99437
        • Zentralklinik Bad Berka GmbH
      • Berlin, Tyskland, 13125
        • Evangelische Lungenklinik Berlin
      • Cologne, Tyskland, 50937
        • Universitaetsklinikum Koeln
      • Cologne, Tyskland, 51109
        • Kliniken der Stadt Koeln gGmbH
      • Gauting, Tyskland, 82131
        • Asklepios Klinik Gauting GmbH - Asklepios Fachkliniken Munchen-Gauting
      • Heidelberg, Tyskland, 69126
        • Thoraxklinik am Universitatsklinikum Heidelberg
      • Heilbronn, Tyskland, 74072
        • Onkologische Schwerpunktpraxis
      • Moers, Tyskland, 47441
        • Bethanien Krankenhaus
      • Oldenburg, Tyskland, 26121
        • Pius-Hospital Oldenburg
      • Recklinghausen, Tyskland, 45659
        • Oncologianova GmbH
      • Dnipro, Ukraine, 49102
        • Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4
      • Kyiv, Ukraine, 02091
        • Medical Center 'Ok Clinic' of LLC 'International Institute of Clinical Studies'
      • Kyiv, Ukraine, 03022
        • National Cancer Institute
      • Budapest, Ungarn, H-1529
        • Orszagos Koranyi Tbc es Pulmonologiai Intezet
      • Gyöngyös, Ungarn, 3233
        • Mátrai Gyógyintézet-Bronchológia
      • Szombathely, Ungarn, 9700
        • Markusovszky Egyetemi Oktatokorhaz
      • Székesfehérvár, Ungarn, 8000
        • Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz
      • Törökbálint, Ungarn, 2045
        • Tudogyogyintezet Torokbalint

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Participant must have histologically or cytologically confirmed, locally advanced or metastatic, nonsquamous non-small cell lung cancer (NSCLC) with documented primary epidermal growth factor receptor (EGFR) Exon 20ins activating mutation
  • Participant must have measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
  • Participant must have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Participant must agree to genetic characterization of tumor status through the required pretreatment tumor biopsy (or submission of equivalent archival material), as well as baseline and periodic blood samples for analysis of tumor mutations in the bloodstream
  • A female participant of childbearing potential must have a negative serum or urine test at screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study

Exclusion Criteria:

  • Participant has evidence of synchronous NSCLC disease (as suggested by genetic characterization or radiographic appearance)
  • Participant has untreated brain metastases (a participant with definitively, locally treated metastases who is clinically stable, asymptomatic, and off corticosteroid treatment for at least 2 weeks prior to randomization is eligible)
  • Participant has history of spinal cord compression that has not been treated definitively with surgery or radiation
  • Participant has a medical history of interstitial lung disease (ILD), including drug-induced ILD, or radiation pneumonitis
  • Participant has a contraindication to the use of carboplatin or pemetrexed (refer to local prescribing information for each agent). Participant has a history of hypersensitivity to, or cannot take, vitamin B12 or folic acid

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Arm A: Amivantamab + Chemotherapy

Participants will receive pemetrexed 500 milligram per meter square (mg/m^2) intravenous (IV) infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin area under the concentration-time curve 5 milligram per milliliter (mg/mL) per minute (AUC 5) will be administered as IV infusion on Day 1 of each 21 day cycle, for up to 4 cycles. Participants will receive amivantamab 1400 mg (1750 mg if body weight is >=80 kilogram [kg]) by IV infusion once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is >=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3. Following the primary analysis for efficacy, the study will transition to an OLE phase and participants will continue to receive the amivantamab plus chemotherapy in OLE phase. Participants who completed OLE period will enter LTE period and continue to receive same treatment.

Amivantamab will be administered as an IV infusion at a dose of 1400 mg (1750 mg if body weight is >=80 kilogram [kg]) by once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is >=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3 and will continue the same treatment in OLE phase then in LTE phase.

Andre navne:
  • JNJ-61186372

Pemetrexed will be administered as 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm A and will continue the same treatment in OLE phase then in LTE phase.

Carboplatin will be administered as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle.

Pemetrexed will be administered as 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm B and will continue the same treatment in OLE phase then in LTE phase.

Eksperimentel: Arm B: Chemotherapy Alone

Participants will receive pemetrexed 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle, in combination with carboplatin for up to 4 cycles, and then as maintenance monotherapy until disease progression. Carboplatin AUC 5 IV infusion will be administered on Day 1 of each 21-day cycle for up to 4 cycles. Following the primary analysis for efficacy, the study will transition to an OLE phase and participants will either continue to receive the chemotherapy or cross over to amivantamab in OLE phase. Participants who completed OLE period will enter LTE period and continue to receive same treatment.

Pemetrexed will be administered as 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm A and will continue the same treatment in OLE phase then in LTE phase.

Carboplatin will be administered as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle.

Pemetrexed will be administered as 500 mg/m^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm B and will continue the same treatment in OLE phase then in LTE phase.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
Tidsramme: From randomization to either disease progression or death whichever occurs first (up to 29 months)

PFS was defined as the time from randomization until the date of objective disease progression based on BICR using RECIST version 1.1 or death (by any cause) in the absence of progression, whichever came first. Participants who have not progressed or have not died at the time of analysis were censored at the time of the latest date of their last evaluable RECIST version 1.1 assessment. Pharmacodynamic: Sum of diameters increased by greater than or equal to (>=)20 percent (%) and >=5 millimeter (mm) from nadir (including baseline if it was smallest sum).

From randomization to either disease progression or death whichever occurs first (up to 29 months)

Sekundære resultatmål

Resultatmål
Tidsramme
Objektiv responsrate (ORR)
Tidsramme: Op til 5 år 3 måneder
Op til 5 år 3 måneder
Varighed af svar (DoR)
Tidsramme: Op til 5 år 3 måneder
Op til 5 år 3 måneder
Samlet overlevelse (OS)
Tidsramme: Op til 5 år 3 måneder
Op til 5 år 3 måneder
Tid til efterfølgende terapi (TST)
Tidsramme: Op til 5 år 3 måneder
Op til 5 år 3 måneder
Progressionsfri overlevelse efter første efterfølgende terapi (PFS2)
Tidsramme: Op til 5 år 3 måneder
Op til 5 år 3 måneder
Tid til symptomatisk progression (TTSP)
Tidsramme: Op til 5 år 3 måneder
Op til 5 år 3 måneder
Antal deltagere Behandlingsfremkaldte bivirkninger (TEAE'er)
Tidsramme: Fra dag 1 til 5 år 2 måneder
Fra dag 1 til 5 år 2 måneder
Antal deltagere TEAE'er med sværhedsgrad
Tidsramme: Fra dag 1 til 5 år 2 måneder
Fra dag 1 til 5 år 2 måneder
Antal deltagere med kliniske laboratorieabnormiteter
Tidsramme: Op til 5 år 3 måneder
Op til 5 år 3 måneder
Antal deltagere med unormale vitale tegn
Tidsramme: Op til 5 år 3 måneder
Op til 5 år 3 måneder
Antal deltagere med unormale fysiske undersøgelser
Tidsramme: Op til 5 år 3 måneder
Op til 5 år 3 måneder
Serumkoncentration af Amivantamab
Tidsramme: Dag 1 (cyklus 1, 2, 3, 5, 7, 9, 11, 13), dag 2 (cyklus 1)
Dag 1 (cyklus 1, 2, 3, 5, 7, 9, 11, 13), dag 2 (cyklus 1)
Antal deltagere med anti-Amivantamab-antistoffer
Tidsramme: Dag 1 (cyklus 1, 2, 3, 5, 7, 9, 11, 13), dag 2 (cyklus 1)
Dag 1 (cyklus 1, 2, 3, 5, 7, 9, 11, 13), dag 2 (cyklus 1)
Ændring fra baseline i European Organization of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)
Tidsramme: Fra baseline til 5 år 3 måneder
Fra baseline til 5 år 3 måneder
Ændring fra baseline i patientrapporterede resultater Måleinformation System-fysisk funktion (PROMIS-PF)
Tidsramme: Fra baseline til 5 år 3 måneder
Fra baseline til 5 år 3 måneder

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

13. oktober 2020

Primær færdiggørelse (Faktiske)

3. maj 2023

Studieafslutning (Anslået)

31. december 2027

Datoer for studieregistrering

Først indsendt

31. august 2020

Først indsendt, der opfyldte QC-kriterier

31. august 2020

Først opslået (Faktiske)

4. september 2020

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

3. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

2. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • CR108850
  • 61186372NSC3001 (Anden identifikator: Janssen Research & Development, LLC)
  • 2023-506033-29-00 (Registry Identifier: EUCT number)
  • 2023 (U.S. NIH-bevilling/kontrakt)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.

As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .